Biography and Research Information
OverviewAI-generated summary
Naveen Yarlagadda's research focuses on multiple myeloma, particularly the clinical significance of minimal residual disease (MRD) negativity. His work investigates the implications of losing MRD negativity after achieving it and identifies persistent MRD as a high-risk disease feature in multiple myeloma patients. Yarlagadda also studies the impact of tandem autologous stem cell transplantation for patients with persistent MRD after an initial transplant. Additionally, his research includes analyzing hematological and infectious complications associated with CD38-targeting monoclonal antibody therapies in multiple myeloma through meta-analyses of randomized control trials. He also examines phenotypic markers and disease progression in monoclonal gammopathy of unknown significance using eight-color flow cytometry. Yarlagadda has a publication record of 21 papers with 398 citations and an h-index of 6. He has collaborated with researchers at the University of Arkansas for Medical Sciences, including Sravani Gundarlapalli, Guido Tricot, Erming Tian, and Sharmilan Thanendrarajan.
Metrics
- h-index: 6
- Publications: 21
- Citations: 405
Selected Publications
-
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)
-
Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials (2021)
-
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)
Collaboration Network
Top Collaborators
Meera Mohan
Froedtert Hospital (US)
5 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Carolina Schinke
University of Arkansas for Medical Sciences
5 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
4 shared publications
In database
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Daisy Alapat
University of Arkansas for Medical Sciences (US)
4 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Frits van Rhee
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Maurizio Zangari
Winthrop Rockefeller Foundation
4 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Anikó Szabó
Froedtert Hospital (US)
3 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Erming Tian
University of Arkansas for Medical Sciences
3 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Guido Tricot
University of Arkansas for Medical Sciences
3 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Samantha Kendrick
University of Arkansas for Medical Sciences
2 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Jeffrey R. Sawyer
University of Arkansas for Medical Sciences (US)
2 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
Shebli Atrash
Levine Cancer Institute (US)
2 shared publications
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Sunilkumar Kakadia
University of Arkansas for Medical Sciences (US)
2 shared publications
- Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Smriti Sharma
Nebraska Medical Center (US)
1 shared publication
- Hematological and infectious complications with CD38 antigen targeting monoclonal antibody-based therapies in multiple myeloma: A meta-analysis of randomized control trials
Similar Researchers
Based on overlapping research topics
Bart Barlogie
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Monica Graziutti
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
O. Makhoul
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Munawar Hussain .
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Bhavesh Mohan Lal
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology